

O/P/E



no location

TECHNOLOGY
SYSTEMS
BRANCH

CRF Problem Report

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: 10/621,485
 Filing Date: 7/16/03
 Date Processed by STIC: 7/28/2003

STIC Contact: Mark Spencer, 703-308-4212

Nature of Problem:

The CRF (was):

- ☐ (circle one) Damaged or Unreadable (for Unreadable, see attached)
- ☐ Blank (no files on CRF) (see attached)
- ☐ Empty file (filename present, but no bytes in file) (see attached)
- ☐ Virus-infected. Virus name: _____ The STIC will not process the CRF.
- ☐ Not saved in ASCII text
- ☐ Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should only be the Sequence Listing.
- ☒ Did not contain a Sequence Listing. (see attached sample)
- ☐ Other: _____

**PLEASE USE THE CHECKER VERSION 4.0 PROGRAM TO REDUCE ERRORS.
 SEE BELOW FOR ADDRESS:**

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry directly to:
 U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name,
 Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
 Or
 U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,
 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,
 Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 04/24/2003

W 566. LIST 4
BE PROCEED

0/621485

C

MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPDVDQREAPLNNFSVAQC 60
QLMKTERPRPNTFIIIRCLQWTTVIERTFHVETPEEREWTTAIQTVADGLKKQEEEEEMDF 120
RSGSPSDNSGAEMEVS LAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKI 180
LKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLS 240
RERVSEDRARFYGAIEVSALDY LHSEKNVVYRDLKLENLMLDKDGH IKITDFGLCKEGI 300
KDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWVG LGVVMYEMMCGRLPFYNQDHEKLFEL 360
ILMEEIRFPRTLGP EAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQH VYEKK 420
LSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA 480

This is not a valid sequence

Listing. It is not in valid

format. Please: 1) consult

Sequence Rules; 2) consult sample

Sequence Listing (attached) for VALID

format.

Also, Per 1.824 d) Sequence Rules,

submit only the Sequence Listing

file on computer readable form. Do

NOT include any other files on

the computer readable form.

<110> Smith, John; Smithgene Inc.
 <120> Example of a Sequence Listing
 <130> 01-00001
 <140> PCT/EP98/00001
 <141> 1998-12-31
 <150> US 08/999,999
 <151> 1997-10-15
 <160>
 <170> PatentIn version 2.0
 <210> 1
 <211> 389
 <212> DNA
 <213> Paramecium sp.

BEST AVAILABLE COPY

<220>
 <221> CDS
 <222> (279)...(389)

<300>
 <301> Doe, Richard
 <302> Isolation and Characterization of a Gene Encoding a
 Protease from Paramecium sp.
 <303> Journal of Genes
 <304> 1
 <305> 4
 <306> 1-7
 <307> 1988-06-31
 <308> 123456
 <309> 1988-06-31

<400>	1						
agcgtgagtc	attccctgtgt	ctctctctct	ctgggcttct	cacctctgct	atcagatctc		60
agggagagtg	ctctgacctt	ctctctgctt	tgcagcttca	caggcaggca	ggcaggcagc	F	120
cgatctgcca	attgctggca	gtgccacagg	cttttcagcc	aggctttagg	tgggttccgc		180
cgcggcgcgg	cggccctctt	cgcgctcttc	tgcgctctct	ctctcgtctt	ctctctgctc		240

Consult this

Appendix 3, page 2

```

ggacctgatt aggtgagcag gaggaggggg cagttcagc atg gtt tca atg ttc agc 296
Met Val Ser Met Phe 5 Ser
ctg tct ttc aaa tgg cct gga tct tgt tct tct gtt tgt tct tct caa 344
Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu Phe Val Cys Leu Phe Cln
10 15 20
tgt ccc aaa gtc ttc ccc tgt cac tca tca ctg cag ccg aat ctt 389
Cys Pro Lys Val Leu Pro Cys His Ser Ser Leu Gln Pro Asn Leu
25 30 35

```

<210> 2
 <211> 37
 <212> PRT
 <213> Paramecium sp.

```

<400> 2
Met Val Ser Met Phe Ser Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu
1 5 10
Phe Val Cys Leu Phe Cln Cys Pro Lys Val Leu Pro Cys His Ser Ser
20 25 30
Leu Gln Pro Asn Leu
35

```

<210> 3
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> Designed peptide based on size and polarity to act as a linker between the alpha and beta chains of Protein XYZ.

```

<400> 3
Met Val Asn Leu Glu Pro Met His Thr Glu Ile
1 5 10

```

<210> 4
 <400> 4
 000

[Annex VIII follows]

BEST AVAILABLE COPY

identifiers and their definitions. Any information as shown in the "Sequence Listing" shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers:

Numeric Identifier	Definition	Comments and Format	Mandatory (M) or Optional (O)
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials	M
<120>	Title of Invention		M
<130>	File Reference	Personal file reference	M, when filed prior to assignment of appl. number
<140>	Current Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if available
<141>	Current Filing Date	Specify as: yyyy-mm-dd	M, if available
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOs	Count includes total number of SEQ ID NOs	M
<170>	Software	Name of software used to create the Sequence Listing	O
<210>	SEQ ID NO: #	Response shall be an integer representing the SEQ ID NO shown	M
<211>	Length	Respond with an integer expressing the number of bases or amino acid residues	M

BEST AVAILABLE COPY

1/29/99 1:53 PM

<212>

Type

Whether presented sequence molecule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/RNA molecule shall be further described in the <220> to <223> feature section.

BEST AVAILABLE COPY

<213>

Organism

Scientific name, i.e. Genus/species. Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.

<220>

Feature

Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.

M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.

<221>

Name/Key

Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6

M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence

<222>

Location

Specify location within sequence; where appropriate state number of first and last bases/amino acids

M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

in feature

base was used in
a sequence

<223>

Other Information

Other relevant
information;
four lines maximum

M, under the following conditions:
if "n," "Xaa," or
a modified or unusual L-amino acid
or modified base
was used in a
sequence; if
ORGANISM
is "Artificial
Sequence" or
"Unknown"; if
molecule is combined DNA/RNA.

<300>

Publication
Information

Leave blank
after <300>

0

<301>

Authors

Preferably max
of ten named
authors of publication; specify
one name per line;
preferable format:
Surname, Other
Names and/or
Initials

0

<302>

Title

0

<303>

Journal

0

<304>

Volume

0

<305>

Issue

0

<306>

Pages

0

<307>

Date

Journal date on which
data published;
specify as yyyy-mm-
dd, 1001-yyyy or
Season-yyyy

0

BEST AVAILABLE COPY

<308>

Database
Accession
Number

Accession number
assigned by database including
database name

0

<309>

Database Entry
Date

Date of entry in
database; specify
as yyyy-mm-dd or
1001-yyyy

0

<310>

Patent Document
Number

Document number;
for patent-type
citations only.
Specify as, for
example, US
07/999,999

0

<311>

Patent Filing
Date

Document filing
date, for patent-
type citations only;
specify as yyyy-mm-dd

<312>

Publication Date

Document publication
date, for
patent-type
citations only;
specify as yyyy-mm-dd

BEST AVAILABLE COPY

<313>

Relevant
Residues

FROM (position) TO
(position)

<400>

Sequence

SEQ ID NO should
follow the
numeric identifier
and should appear
on the line pre-
ceding the actual
sequence

5. Section 1.024 is revised to read as follows:

1.024 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.

(a) The computer readable form required by 1.021(c) shall meet the following specifications:

(1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.

(2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.

(3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.

(4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.

(5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.

(6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.

(b) Computer readable form submissions must meet these format requirements:

(1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;

(2) Operating System: MS-DOS, Unix or Macintosh;

1/29/92 1:51 PM